The Second Affiliated Hospital of Guangxi Medical University
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS]) | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 3 | 2026-07-20 | NCT07208058 | |
| China HeadAche DIsorders RegiStry | Analgesic Overuse Headache, Headache Disorders, Secondary, Tension-Type Headache, brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder, trigeminal autonomic cephalalgia | Recruiting | Not stated | 2026-07-10 | NCT05334927 | |
| Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions | Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, histiocytosis, interstitial lung disease, lung disorder, lymphatic system disorder, respiratory system disorder | Recruiting | Not applicable | 2026-01-27 | NCT07371182 | |
| Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2025-12-24 | NCT05604638 | |
| An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Not stated | 2025-07-08 | NCT06959030 | |
| Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Not applicable | 2024-11-29 | NCT06709274 |